Literature DB >> 11928906

Bone allografts pretreated with a bisphosphonate are not resorbed.

Per Aspenberg1, Jörgen Astrand.   

Abstract

Bisphosphonates bind to bone surfaces and inactivate osteoclasts when they start to resorb the bone. Therefore, immersion of a bone graft in a bisphosphonate solution before implantation may protect it from resorption. We implanted frozen cancellous bone allografts into bilateral bone chambers for 6 weeks in 10 rats. One graft in each pair had been immersed in an alendronate solution (1 mg/mL) for 10 minutes, and then rinsed in saline. Controls underwent the same treatment with saline only. Results were evaluated with histomorphometry. Control grafts were almost entirely resorbed, but alendronate-treated grafts seemed intact. In the treated specimens, two thirds of the space behind the bone ingrowth frontier consisted of graft or host bone, but in the controls, only one fifth. Local graft treatment with a bisphosphonate before insertion seems to be risk-free, and may prevent mechanical graft failure due to resorption in patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11928906     DOI: 10.1080/000164702317281350

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  29 in total

1.  Healing properties of allograft from alendronate-treated animal in lumbar spine interbody cage fusion.

Authors:  Qingyun Xue; Haisheng Li; Xuenong Zou; Mathias Bünger; Niels Egund; Martin Lind; Finn Bjarke Christensen; Cody Bünger
Journal:  Eur Spine J       Date:  2004-07-10       Impact factor: 3.134

2.  Topical bisphosphonate augments fixation of bone-grafted hydroxyapatite coated implants, BMP-2 causes resorption-based decrease in bone.

Authors:  Jorgen Baas; Marianne Vestermark; Thomas Jensen; Joan Bechtold; Kjeld Soballe; Thomas Jakobsen
Journal:  Bone       Date:  2017-01-07       Impact factor: 4.398

3.  The effect of soaking allograft in bisphosphonate: a pilot dose-response study.

Authors:  Thomas Jakobsen; Jørgen Baas; Joan E Bechtold; Brian Elmengaard; Kjeld Søballe
Journal:  Clin Orthop Relat Res       Date:  2009-09-18       Impact factor: 4.176

Review 4.  [Can failed back surgery be prevented? Psychological risk factors for postoperative pain after back surgery].

Authors:  R Klinger; F Geiger; M Schiltenwolf
Journal:  Orthopade       Date:  2008-10       Impact factor: 1.087

5.  Prevention of the surface resorption of bone grafts by topical application of bisphosphonate on different carrier materials.

Authors:  Björn Möller; Jörg Wiltfang; Yahya Acil; Matthias Gierloff; Sebastian Lippross; Hendrik Terheyden
Journal:  Clin Oral Investig       Date:  2014-02-23       Impact factor: 3.573

6.  Local delivery of zoledronate from a poly (D,L-lactide)-Coating increases fixation of press-fit implants.

Authors:  Thomas Jakobsen; Joan E Bechtold; Kjeld Søballe; Thomas Jensen; Stefan Greiner; Marianne T Vestermark; Jørgen Baas
Journal:  J Orthop Res       Date:  2015-07-31       Impact factor: 3.494

7.  Effects of Bisphosphonate Administration on Cleft Bone Graft in a Rat Model.

Authors:  Nicole Cheng; Juyoung Park; Jeffrey Olson; Taewoo Kwon; Deborah Lee; Rachel Lim; Sandy Ha; Reuben Kim; Xinli Zhang; Kang Ting; Sotirios Tetradis; Christine Hong
Journal:  Cleft Palate Craniofac J       Date:  2017-01-17

8.  Biomechanical parameters of the BP-enriched bone cement.

Authors:  Łukasz Matuszewski; Grażyna Olchowik; Tomasz Mazurkiewicz; Bartłomiej Kowalczyk; Agata Zdrojewska; Anna Matuszewska; Andrzej Ciszewski; Małgorzata Gospodarek; Iwona Morawik
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-05-14

9.  Zoledronate reduces unwanted bone resorption in intercalary bone allografts.

Authors:  Sung W Seo; Samuel K Cho; Steven K Storer; Francis Y Lee
Journal:  Int Orthop       Date:  2009-04-03       Impact factor: 3.075

10.  Bisphosphonate delivery to tubular bone allografts.

Authors:  Gene R DiResta; Mark W Manoso; Anwar Naqvi; Pat Zanzonico; Peter Smith-Jones; Wakenda Tyler; Carol Morris; John H Healey
Journal:  Clin Orthop Relat Res       Date:  2008-04-26       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.